Enterome
Created in 2011
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
1,257 309 15,071Global tags
Activities
Technologies
Entity types
Location
94-96 Av. Ledru Rollin, 75012 Paris, France
Paris
France
Employees
Scale: 51-200
Estimated: 74
SIREN
508580289Engaged corporates
14
6 8Added in Motherbase
3 years, 5 months ago
healthtech Value proposition
Delivering the promise of immunotherapy
Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body.
The company is currently developing a pipeline of drug candidates consisting of OncoMimicsTM peptide-based immunotherapies for the treatment of cancer. EO2463 is in a Phase 2 clinical trial for indolent non-Hodgkin lymphoma, demonstrating a benign safety profile with encouraging early signs of efficacy. EO2401 has successfully completed a Phase 2 clinical trial in patients with recurrent glioblastoma, and Enterome is currently seeking a pharmaceutical partner to further develop a pivotal trial.
Immuno-oncology, Auto-immunity, Metagenomics, Immunotherapies, and Onco-hematologyOriginal language
Delivering the promise of immunotherapy
Enterome is a clinical-stage biopharmaceutical company developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Enterome’s pioneering approach to drug discovery is based on its unique and powerful bacterial Mimicry drug discovery platform, which allows it to analyze and uncover new biological insights from the millions of gut bacterial proteins in constant cross-talk with the human body.
The company is currently developing a pipeline of drug candidates consisting of OncoMimicsTM peptide-based immunotherapies for the treatment of cancer. EO2463 is in a Phase 2 clinical trial for indolent non-Hodgkin lymphoma, demonstrating a benign safety profile with encouraging early signs of efficacy. EO2401 has successfully completed a Phase 2 clinical trial in patients with recurrent glioblastoma, and Enterome is currently seeking a pharmaceutical partner to further develop a pivotal trial.
Enterome
We are a clinical stage biopharmaceutical company developing novel drugs to transform human health based on our unique ability to de-code molecular interactions in the gut microbiome.
https://www.enterome.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Not capitalistic Not partnership Event 25 Sep 2017 30 Mar 2023 | | |
 Genopole Biotechnology, Biotechnology Research | Genopole Biotechnology, Biotechnology Research | Not capitalistic Not partnership Event 15 Jan 2021 16 Jun 2023 | | |
 Omnes Startup accelerator & VC, Financial Services | Omnes Startup accelerator & VC, Financial Services | Capitalistic Not partnership Not event 10 Jul 2020 18 Jun 2023 | | |
 SAP IT services, Software, Software Development | SAP IT services, Software, Software Development | Other 9 Jul 2021 | | |